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Osteoporosis in gastric cancer patients is often overlooked or even neglected despite its high prevalence in these patients. Considering 
that old age, malnutrition, chronic disease, chemotherapy, decreased body mass index and gastrectomy are independent risk factors for 
osteoporosis, it is reasonable that the prevalence of osteoporosis in gastric cancer patients would be high. Many surviving patients suf-
fer from back pain and pathological fractures, which are related to osteoporosis. Fractures have obvious associated morbidities, negative 
impact on quality of life, and impose both direct and indirect costs. In the era of a >55.6% 5-year survival rate of gastric cancer and 
increased longevity in gastric cancer patients, it is very important to eliminate common sequelae such as osteoporosis. Fortunately, the 
diagnosis of osteoporosis is well established and many therapeutic agents have been shown to be effective and safe not only in post-
menopausal females but also in elderly males. Recently, effective treatments of gastric cancer patients with osteoporosis using bisphos-
phonates, which are commonly used in postmenopausal woman, were reported.
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Introduction
Gastric cancer is one of the most common cancers in the 
world. Although relatively decreasing in prevalence, it is still the 
second most common cause of death from cancer in the world. 
The incidence of gastric cancer is very high in East Asia, and it is 
a major burden in countries, such as Korea.(1) Although the overall 
prognosis of gastric cancer is poor in Western countries, the 5-year 
survival rate for those who received operative treatment in Korea 
is 55.6%. In cases of early gastric cancer, the survival rate is more 
than 90% in Korea due to early diagnosis and aggressive surgical 
intervention.(2) 
However, many surviving patients unfortunately suffer 
from sequelae caused by the surgical procedure. Weight loss, 
malnutrition, anemia and osteoporosis are known consequences 
of gastrectomy.(3) Old age, malnutrition, chronic disease, 
chemotherapy, decreased body mass index and gastrectomy are 
independent risk factors for osteoporosis. Most gastric cancer 
patients have these risk factors.(4) The prevalence of osteoporosis 
in gastric cancer patients who are older than 50 years old is up 
to 38.3% in Korea.(5) Similar to other primary and secondary 
forms of osteoporosis, most gastrectomy-induced osteoporosis 
patients suffer from back pain and pathologic fractures. Recently, 
a 63-year-old woman who underwent gastrectomy for a gastric 
malignancy spontaneously developed multiple fractures.(6) It was 
speculated that the synergistic effects of gastrectomy and other 
osteoporosis risk factors led to multiple fractures.
The American Gastroenterology Association (AGA) recom-
mended dual-energy X-ray absorptiometry (DXA) evaluation in 
patients who had any of the following conditions: at least 10 years 
postgastrectomy, low-trauma fracture history, such as a vertebral 
fracture, postmenopausal female or male over 50 years of age, and 
hypogonadism.(4) Most of the gastric cancer patients in Korea 
qualified for these conditions.  
In this review article, we discuss the prevalence, pathophysio-
logy, screening, and management of osteoporosis in gastric cancer 
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and postgastrectomy patients. The objective of this review is to 
help to understand a practical diagnostic strategy and to provide 
management recommendations regarding osteoporosis in gastric 
cancer patients. 
The Prevalence of Osteoporosis 
and Fractures in Gastric Cancer or 
Postgastrectomy Patients
The overall prevalence of osteoporosis in Korean gastric cancer 
patients older than 50 years of age was 39.6%.(5) The osteoporosis 
rate of the lumbar spine in gastric cancer patients was 29.8% in 
male and 54.5% in female patients. The osteoporosis rate of the 
femoral neck was 11.9% in males and 26.3% in females.(5) Those 
rates are higher than the osteoporosis rates in a community-based 
Korean study. Cui et al.(7) studied 4,148 Korean adults to assess 
the prevalence of osteoporosis. The osteoporosis rate of the lumbar 
spine in patients over 50 years was 6.5% in male and 40.1% in fe-
male patients. The osteoporosis rate of the femoral neck was 5.9% 
in male and 12.4% in female patients. 
In other DXA-based studies in postgastrectomy patients, in-
cluding gastric cancer and peptic ulcer patients, the prevalence of 
osteoporosis of the lumbar spine was 22~37% and that of the fem-
oral neck was 10~61%.(8,9) In a U.S. population-based study in-
volving 355 males over age 60, 17 had a previous total gastrectomy 
for gastric cancer. Their bone mineral density (BMD) as measured 
by DXA decreased at the spine (-14.1%), total hip (-9%), and distal 
radius (-9.9%).(10) In Korea, mean bone loss in the lumbar spine 
(-5.7%), total hip (-5.4%), and femoral neck (-6.6%) was reported 
1 year after gastrectomy.(11) Thus, even in the more recent studies, 
gastrectomy remains a significant contributor to bone disease. 
In our study, 24 of 133 (18.0%) gastric cancer patients had 
osteoporotic fractures (such as Colles’ fracture, ankle and severe 
vertebral fractures). Of the gastric cancer patients, 61 of 133 (45.9%) 
complained of back pain, and 46.6% showed vertebral bone defor-
mity.(5) In a population-based study from the U.S. which assessed 
438 subjects who underwent peptic ulcer surgery, the estimated in-
cidence of hip fracture was 25% with a relative risk (RR) of 2.5 and 
that of vertebral fracture was 41% with a RR of 4.7.(12) In a Swed-
ish male cohort, gastrectomy patients had a higher fracture rate 
(40% in Billroth I and 33% in a Billroth II) compared to that of the 
controls (12%).(13) At almost 9 years’ follow-up, the postgastrec-
tomy patients had an average of 1.7 spinal fractures compared to 
an average of 0.6 fractures in the controls, representing a threefold 
increase in risk.(14)
Pathogenesis of Osteoporosis in 
Gastric Cancer
The exact pathogenesis of osteoporosis in gastric cancer is un-
known. Old age, female sex, malabsorption, cancer itself and its 
treatment are independent risk factors for osteoporosis. Malabsorp-
tion before and after gastric bypass surgery might play a major role 
as suspected. Deficiency of nutrients such as calcium, phosphorous, 
vitamin D, iron and protein is frequently noted in postgastrec-
tomy patients. Poor absorption of vitamin D and calcium results 
in secondary hyperparathyroidism, which increases rates of bone 
loss. In addition, low vitamin D levels or hypocalcemia can lead to 
osteomalacia or osteoporosis. Chemotherapy can also affect bone 
metabolism, as it does in other cancer patients; however, evidence 
is limited. 
1. Malabsorption and malnutrition
Removal of the gastric antrum with anastomosis to the duode-
num (Billroth I) or with anastomosis to the jejunum (Billroth II) 
alters normal gastrointestinal (GI) physiology. Consequently, calci-
um malabsorption follows because calcium is absorbed primarily in 
the duodenum. Gastric dumping or formation of insoluble calcium 
soaps due to fat malabsorption may also cause calcium malabsorp-
tion. Mean serum calcium levels were found to be lower than those 
in controls.(15,16) One study showed 7.3% out of 342 postgastrec-
tomy patients had subnormal serum calcium levels, compared with 
only 0.5% of controls.(16) However, in the clinical setting, it is dif-
ficult to find low calcium levels in postgastrectomy patients because 
on average, the serum calcium level still falls into the lowest levels 
of normal range.(17) 
After gastrectomy, patients often suffer from steatorrhea, lead-
ing to malabsorption of vitamin D.(18) However, in clinical studies, 
vitamin D malabsorption in postgastrectomy patients was mild or 
normal at worst.(15) After gastrectomy, patients may alter their diet, 
and decreased serum 25-hydroxyvitamin D (25-OHD) level may 
in part reflect reduced dietary intake of vitamin D.(18) Patients who 
had subnormal 25-OHD levels generally had longer duration after 
gastrectomy.
Protein metabolism has an obvious role in the formation of the 
collagen matrix of bone. Impaired protein nutrition secondary to 
reduced intake may also play a role in postgastrectomy bone dis-
ease.(3,19) The BMD of the total hip, femoral neck, and trochanter Osteoporosis in Gastric Cancer Patient
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also correlated to the change in body weight at 12 months.(11) The 
standard recommended daily allowances (RDAs) of nutrients are 
often inadequate, and gastric cancer patients require much more 
intake, although weight loss and nutrition are stabilized over time 
after gastrectomy.
2. Hyperparathyroidism
Hyperparathyroidism is associated with osteoporosis. The para-
thyroid hormone (PTH) activates osteoblasts, which in turn matures 
the osteoclasts. Osteoclasts release hydrochloric acid, which dis-
solves bone mineral, causing osteopenia and osteoporosis.(20)
Serum calcium, phosphate and vitamin D may be maintained at 
the expense of bone mass. Bone-related hormones, such as PTH, 
play an important role in regulation of calcium homeostasis. Sec-
ondary hyperparathyroidism could explain these results. Elevated 
PTH was reported in some studies,(21) although most studies re-
port PTH levels within normal range.(17,22) However, those stud-
ies are cross-sectional and different from each other in sampling 
timing after gastrectomy. 
Recently, Baek et al.(11) found that serum PTH levels were 
increased after gastrectomy in gastric cancer patients. Patients who 
had higher PTH levels after gastrectomy lost more bone at the 
lumbar spine and total hip during the first year after gastrectomy. 
Bone resorption markers increased without an associated increase 
in bone formation markers after the early gastrectomy-period. 
Such an uncoupling of bone metabolism suggests that postgastrec-
tomy bone loss is a consequence of an imbalance between bone 
formation and bone resorption. Bone resorption markers, bone 
formation markers, and PTH were all normalized 1 year postgas-
trectomy, which indicates adequate coupling and discontinuation of 
active bone loss. Significant correlations were found between the 
percent change in the BMD at the lumbar spine and total hip and 
that of the PTH level from their baseline to 12 months. In an ani-
mal study, total gastrectomy resulted in reduced serum calcium and 
25-OHD and increased PTH compared with sham-operated con-
trols.(23) In secondary hyperparathyroidism, elevated 1,25(OH)2-
vitamin D levels and enhanced 25-OHD clearance can be reversed 
with adequate nutrition such as oral calcium supplementation and 
higher doses of vitamin D.(24)
3. Chemotherapy 
A variety of cancer therapies, including hormonal therapy, 
chemotherapy, and radiotherapy affect bone metabolism.(25) In 
vitro chemotherapeutic agents can interfere with osteoblast func-
tion, cause adverse effects on mineralization by osteoblasts, and 
reduce the number of osteoblasts.(26) The most commonly used 
chemotherapeutic agents for gastric cancer is doxifluridine and 
cisplatin; 5-fluorouracil was reported to induce apoptosis among 
osteoblasts and preosteoblasts in animal models.(27) Cisplatin 
treatment showed increased osteoclast activity and delayed bone 
formation during the remodeling phase in an animal model.(28) 
Bone formation marker levels were generally lower for the patients 
who received chemotherapy than for the patients who did not.(11) 
In conclusion, systemic adjuvant chemotherapy in postgastrectomy 
cancer patients may account for the uncoupling of the markers of 
bone formation during the early postgastrectomy period, and it is 
probable that the chemotherapeutic agents contribute to the more 
severe bone loss noted for patients who received chemotherapy.
4. Other
Inflammatory cytokines, such as tumor necrosis factor (TNF)-
a, IL-6, and IL-1, are often increased in gastrointestinal disease 
patients including those with gastric cancer.(29) TNF-a inhibits 
differentiation of osteoblasts from pluripotent progenitor cells as 
well as the expression of a critical transcription factor required for 
osteoblast differentiation. TNF-a also induces osteoclast differen-
tiation and increases osteoclastic bone resorption. TNF-a also in-
hibits bone collagen synthesis in vitro. TNF-a inhibits the action of 
1,25 (OH) vitamin D through activation of a nuclear inhibitor that 
antagonizes the effect of vitamin D.(30) However, reports on the 
relationship of cytokine and bone metabolism in gastric cancer are 
scarce. 
Calcitonin has osteoclast-inhibiting effects. Decreased calcitonin 
may favor bone resorption. One study found that the serum calci-
tonin levels were significantly reduced in postgastrectomy patients.  
The destruction of gastric acid after gastrectomy also might 
result in osteoporosis. Epidemiologic studies suggest an associa-
tion between the use of protein pump inhibitors, low bone density, 
and fractures.(31) The proposed mechanism of action is decreased 
gastric acidity causing a decrease in absorption of calcium although 
this theory has been questioned yet. 
Screening and Diagnosis of Osteoporosis 
in Gastric Cancer
Gastric cancer patients over 50 years of age should be screened 
for the risk factors for fracture and bone mineral density by DXA. 
Selected patients with high risk of osteoporosis should consider Lim JS and Lee JI
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blood tests, such as tests for calcium, phosphorus, 25-OHD, PTH, 
bone markers, estrogen in females, and testosterone in males. If 
specific risk factors are detected, work up by a specialist is essential. 
There are no specific osteoporosis screening guidelines for gas-
tric cancer patients, but the AGA recommends DXA screening in 
postgastrectomy patients with any of following conditions: low-
trauma fracture history, such as a vertebral fracture, postmenopaus-
al female or male over 50 year of age, and hypogonadism.(4) The 
Korean Society of Bone Metabolism also recommends DXA in 
patients with risk factors, such as malabsorption and chemotherapy.
(32) The risk factors commonly associated with fracture are listed 
in Table 1.(33) However, a risk factor grading system for GI disor-
ders was not established; only low body weight, smoking, exercise, 
disease activity, menstrual status, corticosteroid use, dietary calcium 
intake, family history of osteoporosis, and personal history of frac-
tures are candidates. Patients with one or more known risk factors 
probably should undergo initial screening with DXA. In this regard, 
most gastric cancer patients after gastrectomy should be screened 
for bone mineral density by DXA. Indications for BMD testing by 
The Korean Society of Bone Metabolism are listed in Table 2.(32) 
DXA is the gold standard for the non-invasive diagnosis of os-
teoporosis.(4,33) The World Health Organization (WHO) reported 
a classification of BMD for the diagnosis of osteoporosis based on 
DXA (Table 3).(33) T-score in DXA reports is defined as the num-
ber of standard deviations away from the mean BMD of a healthy 
young population. Several epidemiological studies have confirmed 
the association between a low BMD T-score and fracture risk in 
the elderly population. The fracture risk doubles for every SD de-
crease in BMD T-score. 
Table 1. Relative risk factors of fracture 
Risk factor  Relative risk
Five or more clinical features of following: 1) age over 
80 years; 2) maternal history of hip fracture; 3) any 
fracture after the age of 50 years; 4) fair to poor 
health; previous hyperthyroidism; 5) anticonvulsant 
therapy; 6) long-acting benzodiazepine therapy; 7) 
weight or height less than at the age of 25 years; 8) 
more than two cups of coff  ee consumed per day; 9) 
standing less than four hours per day; 10) no walking 
for exercise; 11) inability to stand from sitting; 12) 
poor depth perception or contrast sensitivity; and 
13) pulse rate higher than 80 per minute. 
17.3
Two or more previous vertebral fractures 11.8
Previous non-spinal fracture   2.4 
Tobacco use   5.6
Body mass index less than 23   5.4
Any vision problem   3.3 
Increasing age over 65 years (by 10 years) 2.0 to 2.9
Anticonvulsant therapy    2.8
Postmenopausal status   2.5
Demineralization identifi  ed on radiographs    2.4
Increased postural instability    2.2
Inability to stand up from sitting position   2.1
Mother with hip fracture   2.0
Adapted from (33).
Table 2. Indications for bone mineral density testing 
1) Premenopausal women with amenorrhea longer than 6 months
2) Women during the menopausal transition with risk factors for 
osteoporosis
3) Postmenopausal women
4) Men under age 70 with risk factors for osteoporosis
5) Men aged 70 and older
6) Adults with a fragility fracture
7) Adults with radiologic fi  nding of vertebral fracture or osteopo-
rosis
8) Adults with diseases or taking medications associated with 
secondary osteoporosis
9) Anyone being considered for pharmacologic therapy
10) Anyone being treated, to monitor treatment eff  ects
Adapted from Th   e Korean Society of Bone Metabolism.(32)
Table 3. World Health Organization (WHO) defi  nition of osteoporosis
Diagnostic category T-score Bone mineral density
Normal >–1 Within 1 SD of a young normal adult
Low bone mass –1 to –2.5 Between 1 and 2.5 SD below that of a young normal adult
Osteoporosis <–2.5 >2.5 SD below that of a young normal adult
Severe osteoporosis <–2.5 and >1 fragility fracture >2.5 SD below that of a young normal adult
Adapted from WHO Technical Report Series.(33)Osteoporosis in Gastric Cancer Patient
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25-hydroxyvitamin D should be measured in patients at risk 
for malabsorption with a target blood level of 30 ng/ml because 
secondary hyperparathyroidism is initiated when vitamin D is less 
than this level.(24) Serum levels of the active metabolite 1,25 dihy-
droxyvitamin D do not correlate with nutritional stores and need 
not be measured. 
Measuring serum PTH levels and 24-hour urine calcium col-
lection may be useful in select patients. Secondary hyperparathy-
roidism and low urinary calcium levels may be seen in patients 
with severe malabsorption or low vitamin D and may be useful for 
monitoring the replacement therapy. 
Management of Osteoporosis in 
Gastric Cancer
The management algorithm for osteoporosis in gastric cancer 
patients is shown in Fig. 1. All gastric cancer patients with T scores 
between -1.0 and -2.5 are associated with high risks of fracture, 
and pharmacologic therapy should be considered. Calcium and 
vitamin D supplements are generally required. In addition, in some 
cases such as T score lower than -2.5, bisphosphonates should be 
considered. Indications for pharmacologic therapy in postmeno-
pausal women and men over 50 years of age by the Korean Society 
of Bone Metabolism are listed in Table 4. It is well known that 
postgastrectomy patients have higher risks of both hip and verte-
bral fractures.(13,14)
The first goal in managing osteoporosis in gastric cancer patients 
is to restore adequate nutrition and prevent hyperparathyroidism to 
prevent further bone loss. The final goal is to prevent fractures and 
maintain a healthy life to improve quality of life in gastric cancer 
patients. 
1. Physical activity
Physical activity is necessary for bone formation and mainte-
nance throughout life. Weight training has been shown to induce a 
small increase in BMD at some, but not all skeletal sites. Walking 
has not demonstrated to increase BMD or to reduce fracture risk, 
but improvements in mobility, muscle function, and balance may 
Table 4. Indications for pharmacologic therapy in postmenopausal 
women and men aged 50 and older 
1) Hip or vertebral fracture
2) Osteoporosis (T score below -2.5)
3) T score between -1.0 and -2.5 with other prior fractures
4) T score between -1.0 and -2.5 with secondary causes associated 
with high risk of fracture
5) T score between -1.0 and -2.5 with either a 10-year hip fracture 
probability of 3% or more or 10-year any major osteoporosis-
related fracture probability of 20% or more
Adapted from Th   e Korean Society of Bone Metabolism. (32)
Fig. 1. Th   e management approach for osteoporosis in gastric cancer patients. DXA = dual-energy X-ray absorptiometry; PTH = parathyroid hor-
mone.Lim JS and Lee JI
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reduce fracture risk by decreasing the risk of falling.
2. Nutrition and calcium/vitamin D supplemen  ta-
tion 
Calcium and vitamin D supplements are generally required, as 
the standard RDAs are rarely met with diet only in gastric cancer 
patients. Considering that average calcium and vitamin D intake of 
Korean is not sufficient,(34) it is essential to supplements all gastric 
cancer patients. The RDA for calcium is 1,000 mg per day for men 
and premenopausal women and 1,000~1,500 mg per day for post-
menopausal women.(32,35) As the average daily calcium intake is 
less than 500 mg in people 50 years and older, most gastric cancer 
patients will need 500~1,000 mg daily as a supplement. The current 
RDA of vitamin D 400 IU per day is clearly inadequate, The Na-
tional Osteoporosis Foundation recommends routine supplementa-
tion with 800~1,000 IU daily. Many patients have vitamin D mal-
absorption and require even higher doses. If the baseline 25-OHD 
level is lower than 15 ng/ml, most recommendations are to admin-
ister 50,000 units per week for 8`~12 weeks and then reevaluate.
(24) The goal is to maintain the serum levels of 25-OH vitamin D 
at 30 ng/ml or higher. Higher levels of vitamin D have fewer side 
effects and are supposed to have possible additional health benefits.
(24) It is particularly important to replace calcium and vitamin D in 
patients when beginning antiresorptive therapy, such as bisphos-
phonates, because treatment can induce hypocalcemia. The usual 
recommended doses of calcium and vitamin D are listed in Table 5.
Most gastric cancer patients experience a rapid weight loss dur-
ing the immediate postoperative period. They also experience lack 
of appetite, dyspepsia, altered intestinal motility, and dysphagia, 
which are explanatory factors of the low food intake.(3) Low en-
ergy intake and fecal energy loss (inadequate absorption) is sug-
gested to be an important mechanism. The mean energy imbal-
ance is approximately 390 kcal/d 6 months after gastrectomy and 
about 310±50 kcal/d 5 years after the operation.(3) As a result, 
Table 5. Recommendations for calcium and vitamin D supplementation 
Indication Dosage
Calcium Supplementation recommended for 
most men and women aged >50 yr
Total intake 1,000 to 1,500 mg/day (adjust dosage according to dietary 
  calcium intake)
Vitamin D Supplementation recommended for
most men and women
Age 51 to 70 yr: 400 IU/day
Age >70 yr: 600 IU/day
In patients at risk for deficiency because of inadequate sunlight exposure: 
  800 IU/day
Adapted from Th   e Korean Society of Bone Metabolism and National Institutes of Health.(32,35)
Table 6. Commonly used medication in osteoporosis 
Indication Dosage Note
Alendronate Prevention and treatment of 
osteoporosis in postmenopausal 
women
Prevention: 5 mg/day or 35 mg/wk 
Treatment: 10 mg/day or 70 mg/wk
Increased risk of gastrointestinal side 
eff  ects and suboptimal absorption; 
contraindicated in patients with 
swallowing abnormalities or who cannot 
remain upright aft  er dosing
Ibandronate Prevention and treatment 150 mg/mo
Risedronate Prevention and treatment: 5 mg/day or 35 
mg/wk
Teriparatide Treatment of osteoporosis in 
postmenopausal women at high 
risk for fracture
20 μg/day (subcutaneous injection) Teriparatide given to rats for most of their 
lifetime caused some rats to develop a 
form of bone cancer. Use of the drug for 
>2 years not recommended 
Calcitonin Treatment of postmenopausal 
osteoporosis in women who have 
been menopausal for >5 yr
200 IU/day intranasally;
alternate nostrils daily
Generally safe; patients may experience 
rhinitis or epistaxis
Adapted from Th   e Korean Society of Bone Metabolism and National Osteoporosis Foundation.(32)Osteoporosis in Gastric Cancer Patient
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approximately 10% loss of the preoperative weight occurs during 
the early postoperative period.(11) Previous studies showed that a 
10% weight loss resulted in 1~2% bone loss in various sites. Thus, 
proper nutrition is essential to prevent osteoporosis in gastric cancer 
patients. 
3. Pharmacologic intervention
Bisphosphonates, selective estrogen receptor modulators 
(SERMs), calcitonin, teriparatide, and estrogen reduce the risk of 
fracture in osteoporosis patients, and the US Food and Drug Ad-
ministration (FDA) approved these therapeutic options for treat-
ment or prevention of osteoporosis.(32) The commonly prescribed 
medicines are listed on Table 6. However, only bisphosphonates 
showed effectiveness in a clinical trial of gastric cancer patients un-
til now.(36) 
4. Bisphosphonates 
Bisphosphonates are stable analogues of pyrophosphate with a 
strong affinity for bone apatite; these agents inhibit bone resorp-
tion by reducing the recruitment and activity of osteoclasts and 
increasing apoptosis of osteoclasts.(37,38) The bones formed while 
patients are receiving bisphosphonates treatment is histologically 
normal. 
5. Alendronate
Iwamoto et al.(36) reported successful treatment with alendro-
nate (5 mg daily and 35 mg weekly) in postgastrectomy osteo-
porotic patients. They treated 24 postgastrectomy patients (mostly 
gastric cancer patients) for 24 months. Lumbar BMD increased by 
5.2% following reductions in urinary levels of N-telopeptides of 
bone type I collagen (NTx) (-27.0% at 3 months) and serum levels 
of ALP (-11.2% at 24 months). Alendronate sodium is indicated 
for the prevention (5 mg daily and 35 mg weekly) and treatment 
(10 mg daily and 70 mg weekly) of osteoporosis in postmenopausal 
women.(39) Alendronate has been shown to increase bone mass 
and to reduce the incidence of fractures of the hip and spine in the 
treatment of preexisting osteoporosis. Alendronate is also indicated 
to increase bone mass in men, and to treat glucocorticoid-induced 
osteoporosis and Paget’s disease of bone in both men and women.(39) 
The efficacy of alendronate 10 mg once daily in increasing bone 
mass was tested in postmenopausal women with osteoporosis ages 
44 to 84.(39) Significant increases in BMD relative to baseline and 
placebo were observed at each measurement site in the lumbar 
spine, trochanter, femoral neck, forearm, and total body. Weekly 
alendronate formulations have efficacy and tolerability similar to 
that of the daily formulations. In the randomized, double-blind, 
placebo-controlled Fracture Intervention Trial (FIT), patients with 
one or more baseline radiographic vertebral fractures, alendronate 
significantly reduced the risk of recurrent vertebral fracture, symp-
tomatic vertebral fracture, hip fracture, and wrist fracture at 3 years.
(40) Among women who were 6 months into menopause, alen-
dronate prevented bone loss in the majority of patients at the spine, 
hip, and total body and reduced the rate of bone loss at the forearm 
by approximately 50%. 
The oral bioavailability of bisphosphonates is low, ranging from 
1 to 3% of the ingested dose.(38) To achieve optimum absorp-
tion and tolerability, patients should take their pill with a full glass 
of water and avoid food and beverages for 30 minutes after the 
morning dose. Importantly, patients must remain upright for 30 
minutes after their first meal of the day. Failure to follow these 
guidelines increases the risk of esophageal side effects and reduces 
the absorption of the medication.(39) When dosing recommenda-
tions are followed, the safety profile of bisphosphonates is generally 
favorable; mild gastrointestinal discomfort (e.g., dyspepsia, and 
abdominal pain) is the most common side effect.(38) Esophagitis 
has been reported with alendronate.(39) Hypocalcemia can occur 
if the patient has pretreatment calcium or vitamin D deficiency or 
renal insufficiency with secondary hyperparathyroidism. Hypocal-
cemia should be managed with 1,000 mg calcium and 800~1,000 
IU vitamin D daily before bisphosphonates. Of particular concern 
are the reports of osteonecrosis of the jaw among patients receiving 
bisphosphonates.(38) However, it should be noted that the majority 
of these patients (87%) were receiving high-dose bisphosphonates 
for indications other than osteoporosis. Other bisphosphonates 
such as risedronate and ibandronate are also available in Korea and 
showed similar efficacy.(34) Zoledronate or pamidronate can be 
used as intravenous therapy because these bisphosphonates show 
fewer GI side effects. 
We treated some gastric cancer patients with severe GI side ef-
fects with the oral bisphosphonate, pamidronate. Pamidronate was 
also effective and patients had fewer GI symptoms (unpublished 
data). Parenteral bisphosphonates can cause a minor acute-phase 
reaction or flu-like syndrome in up to 20~22% of patients.(38) 
The incidence is much lower with repeated doses. Rapid infusions 
of parenteral pamidronate or zoledronate can alter renal function 
and cause rare cases of renal failure. The FDA has approved this 
therapy only for patients with a creatinine clearance of greater than 
35 ml/min.Lim JS and Lee JI
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Conclusions
Gastric cancer patients should be screened for their BMD levels 
using DXA and for other risk factor in accordance with current 
osteoporosis treatment guidelines. These patients have a very high 
prevalence of osteoporosis. Similar to other primary and secondary 
forms of osteoporosis, most gastric cancer patients with gastrec-
tomy suffer from back pain and pathologic fractures. Many patients 
who sustain a hip fracture do not regain full mobility, often requir-
ing nursing home care, which means the profound decrease in 
quality of life.
BMD assessment by DXA assists with the diagnosis of osteopo-
rosis and monitoring of treatment effects in gastric cancer patients. 
The treatment algorithm summarized in this review show effective 
and well-tolerated treatments for GI patients, including gastric can-
cer patients. Calcium and vitamin D are needed separately or with 
bisphosphonates. 
Further research is needed to help define the magnitude of the 
excessive risk of fracture in patients with gastric cancer. Further-
more, the best treatment or prevention schedule for osteoporosis in 
gastric cancer patients has not been clearly defined because there is 
not sufficient evidence. Thus, prospective data are needed to deter-
mine which pharmacologic intervention is more effective and safe. 
These efforts will lead to improving the quality of life of long term 
survival gastric cancer patients. 
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